MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/qai.0000000000001566

Медицинская библиотека · Journal of acquired immune deficiency syndromes (1999) · 2018

Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.

Tang Eric C, Vittinghoff Eric, Anderson Peter L, Cohen Stephanie E, Doblecki-Lewis Susanne, Bacon Oliver, Coleman Megan E, Buchbinder Susan P, Chege Wairimu, Kolber Michael A, Elion Richard, Shlipak Michael, Liu Albert Y

СтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

HIV preexposure prophylaxis (PrEP) using daily oral tenofovir-disoproxil-fumarate/emtricitabine (TDF/FTC) is effective for preventing HIV acquisition, but concerns remain about its potential kidney toxicity. This study examined kidney function in individuals using PrEP in real-world clinical settings.

SETTING

Demonstration project in 2 sexually transmitted infection clinics and a community health center.

METHODS

We evaluated kidney function among men who have sex with men and transgender women taking tenofovir-disoproxil-fumarate/emtricitabine PrEP for up to 48 weeks. Serum creatinine and urine dipstick for protein were obtained at 12-week intervals. Kidney function was estimated using creatinine clearance (CrCl) (Cockcroft-Gault) and estimated glomerular filtration rate (eGFR) (CKD-EPI).

RESULTS

From October 2012 to January 2014, we enrolled 557 participants (median age 33). Mean creatinine increased from baseline to week 12 by 0.03 mg/dL (4.6%) (P < 0.0001); mean CrCl decreased by 4.8 mL/min (3.0%) (P < 0.0001). These changes remained stable through week 48 (P = 0.81, P = 0.71 respectively). There were 75/478 (15.7%) participants who developed worsening proteinuria at week 12 compared with baseline (P < 0.0001), and this percent remained stable through week 48 (P = 0.73). Twenty-five participants (5.1%) developed new-onset eGFR <70 mL/min/1.73 m; independent predictors of this outcome were age ≥40 years (OR 3.79, 95% CI: 1.43 to 10.03) and baseline eGFR <90 mL/min/1.73 m (OR 9.59, 3.69-24.94).

CONCLUSIONS

In a demonstration setting, daily tenofovir-disoproxil-fumarate/emtricitabine PrEP leads to reduced CrCl and eGFR; however, these eGFR changes are based on very small changes in serum creatinine and seem to be nonprogressive after the first 12 weeks. Future studies are needed to understand the prognostic significance of these small changes.

Для цитирования: Tang Eric C, Vittinghoff Eric, Anderson Peter L, Cohen Stephanie E, Doblecki-Lewis Susanne, Bacon Oliver, Coleman Megan E, Buchbinder Susan P, Chege Wairimu, Kolber Michael A, Elion Richard, Shlipak Michael, Liu Albert Y. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.. Journal of acquired immune deficiency syndromes (1999). 2018. DOI: 10.1097/qai.0000000000001566.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.